Anti-CD19-Anti-CD3 IgG format bispecific antibody is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested for specific activity in the functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of CD19-CHO cells (BPS Bioscience #79561-H) that overexpress CD19.
assay conditions: Experimental design and assay protocol for measuring anti CD19-anti CD3 functional activity using NFAT-luc reporter Jurkat cell line:Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-luc (BPS Bioscience #60621) are incubated with increasing concentrations of anti-CD19 x anti-CD3 bispecific antibody in the presence of CD19-CHO cells (BPS Bioscience #79561-H) or CHO cells (ATCC #CCL-61). 1. Seed CHO and CD19-CHO cells at 30,000 cells/well and allow a few hours for the cells to attach in a 96-well clear bottom white plate. 2. Seed Jurkat cells at 30,000 cells/well. 3. Add the bispecific antibody at a recommended dilution range of 100 fM-100 nM. The bispecific antibody simultaneously binds to TCR/CD3 on the NFAT-luc Jurkat reporter cells and tumor antigen CD19 on CD19-CHO cells. 4. After 16 hours the luciferase activity is measured using ONE-Step luciferase assay (BPS Bioscience #60690) per recommended protocol. The bispecific antibody interaction stimulates NFAT-luciferase activity.
Formulation
8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol
Molecular Weight
Heavy Chain: 50 kDa; Light Chain: 24 kDa
Species
Human
Note
Avoid freeze/thaw cycles.
Format
Aqueous buffer solution
Purification
Protein A affinity purification of the IgG-tag protein from HEK293 cells.